Peptide Dosing Protocol Design

Many research peptides require a period of initial saturation before steady-state plasma and receptor levels are achieved. A loading phase delivers higher doses or more frequent administrations during the first 1–2 weeks to accelerate tissue distribution and receptor occupancy — particularly relevant for peptides with slow peripheral compartment equilibration (e.g., BPC-157, TB-500) or those requiring upregulation of downstream signaling machinery (e.g., GH axis peptides building IGF-1 reservoir). Loading phases are not universally necessary. For compounds with short half-lives and fast equilibration (e.g., ipamorelin, most GLP-1 analogs administered to steady state), initiating at the maintenance dose is scientifically appropriate.

A standard loading phase runs 5–14 days at 1.5–2× the maintenance dose or increased frequency (e.g., twice-daily instead of once-daily). The maintenance phase then drops to the target dose for the duration of the research cycle. Example — BPC-157 research protocol: • Loading (Weeks 1–2): 300 mcg twice daily • Maintenance (Weeks 3–12): 250 mcg once daily Example — CJC-1295 No DAC + Ipamorelin combination: • Loading phase is generally not used. Begin at maintenance dose. Pulsatile GH release is the primary endpoint, not receptor upregulation.

Omit a loading phase when: (1) the compound has a half-life under 2 hours, (2) the research endpoint is acute response rather than cumulative effect, (3) the study design requires controlled onset tracking from a defined starting point, or (4) the compound carries dose-dependent tolerability concerns that make upward titration more appropriate than loading.

Growth hormone secretagogues (GHRH analogs, GHRPs, ghrelin mimetics) must be administered in alignment with the endogenous GH pulse rhythm to achieve maximal effect. Endogenous GH pulsatility follows a circadian pattern with the largest pulse occurring 1–2 hours after sleep onset, driven by decreased somatostatin tone during deep sleep. Protocol guidance for GH axis peptides: • Pre-sleep (60 min before bed): Optimal for maximizing natural GH pulse amplitude. Sermorelin, CJC-1295 No DAC, and ipamorelin all produce the strongest IGF-1 response in pre-sleep protocols (Vittone 1997; Sigalos 2018 meta-analysis). • Post-exercise: A secondary optimal window. Exercise transiently reduces somatostatin tone. Administration within 30 minutes post-training captures elevated GHRH receptor sensitivity. • Fasted morning: Acceptable for studies targeting daytime GH monitoring. Somatostatin tone is lower in the early morning than midday. • Avoid midday/post-meal: Postprandial insulin elevation and elevated somatostatin tone significantly blunt GH response. Administering GH secretagogues within 90 minutes of a high-carbohydrate meal reduces response by 40–60% in murine models.

Semaglutide, tirzepatide, and retatrutide have half-lives of 5–7 days (semaglutide), ~5 days (tirzepatide), and ~6 days (retatrutide), making precise administration timing less critical for steady-state endpoints. Weekly administration on a consistent day is standard for the DIO rodent models and human Phase 2/3 protocols. For food intake and glycemic studies with acute endpoints, administration 30–60 minutes pre-meal is the published standard for GLP-1R agonists.

BPC-157, TB-500, and GHK-Cu do not have strong circadian timing dependencies. Research protocols typically divide daily doses into AM/PM administrations for tissue saturation studies, or use a single daily administration for maintenance protocols. Consistency of timing across study days is more important than the specific time chosen.

Semax, Selank, DSIP, and oxytocin have behavioral and cognitive endpoints that interact with circadian cortisol curves. Protocols targeting anxiety-like behavior (EPM, open field) or cognitive endpoints (Morris Water Maze, novel object recognition) typically administer in the early active phase of the rodent light cycle (i.e., at lights-off for nocturnal rodents). Timing relative to behavioral testing is a critical design variable to specify in the protocol.

Repeated subcutaneous injections at the same site cause lipohypertrophy (fatty tissue fibrosis), compromised absorption kinetics, and local inflammatory artifact that confounds study endpoints. Systematic site rotation is not optional in multi-week research protocols — it is a design requirement for reproducible pharmacokinetics.

For human research protocols, standard rotation zones are: (1) periumbilical abdomen (left quadrant, right quadrant), (2) anterior/lateral thighs (left, right), and (3) dorsolateral upper arms. A 6-zone rotation schema completes a full cycle before returning to the starting site, providing 6+ days of recovery per site — sufficient to prevent lipohypertrophic changes in most protocols. For subcutaneous dosing in rodents, rotate between dorsal neck scruff (primary), interscapular, and lumbar-dorsal sites. Avoid consecutive injections within 1 cm of a prior site.

Log each injection site in your protocol record. Format: [Date / Time / Site Code / Volume / Compound]. Example: "2026-01-15 / 08:00 / ABD-L / 0.10 mL / BPC-157 250 mcg". This enables retrospective analysis if site-specific absorption differences are observed.

A 12-week cycle is the standard minimum duration for evaluating chronic tissue remodeling endpoints: collagen synthesis (BPC-157, GHK-Cu), bone mineral density changes (GHRH analogs, PTH fragments), body composition shifts (GLP-1 agonists, MOTS-c, MK-677), and baseline IGF-1 trajectory establishment. 12 weeks provides: • 3 complete monthly biological rhythms (menstrual cycle data in female cohorts, cortisol circadian entrainment) • Sufficient duration to separate transient acute effects from sustained remodeling responses • Adequate time for blood biomarker stabilization (IGF-1 reaches new steady state within 4–6 weeks for GH axis peptides; 8–12 weeks for body composition endpoints) • Standard duration aligned with published Phase 1/2 clinical protocols for most compound classes Use a 3-month cycle when: studying acute-to-chronic transition, running proof-of-concept pilots, or evaluating compounds with well-documented rapid effects.

A 24-week cycle is required for endpoints involving slower biological processes: bone remodeling (3–6 month turnover cycle), metabolic set-point adaptation, telomere dynamics (Epitalon protocols), cardiac structural remodeling, or cognitive neuroplasticity measures. Notable published protocols using 24-week durations: • Tesamorelin HIV-lipodystrophy trials (Lo 2010 NEJM): 26 weeks for stable VAT reduction • Semaglutide SCALE trial: 56 weeks (two 6-month cycles) • MK-677 long-term safety: 2-year protocol with 6-month interim analyses (Nass 2008) 6-month cycles also allow detection of delayed adverse effect profiles (e.g., insulin resistance signals with MK-677, CJC-1295 DAC GH blunting with continuous exposure) that may not manifest in shorter protocols.

For multi-vial compounds requiring sequential reconstitution (any lyophilized peptide with ≤4 week reconstituted stability), monthly ordering intervals align with reconstitution cycles. Calculate your total monthly dose budget and order accordingly: Monthly vials needed = (Daily dose mcg × 30 days) ÷ (Vial size mcg × practical yield factor of 0.95) The 0.95 factor accounts for the ~5% volume left in vials after normal aspirations and accounts for syringe dead space in 0.3 mL insulin syringes.

Washout duration should be calculated as a multiple of the compound's half-life. Standard thresholds: • 5 half-lives: ~97% clearance — sufficient for most research endpoints • 7 half-lives: ~99.2% clearance — required when receptor baseline normalization is a study objective • 10 half-lives: ~99.9% clearance — use when co-administration study crossover design requires complete prior-compound elimination Examples: • Ipamorelin (half-life 2 h): 5×2h = 10 hours minimum washout • Semaglutide (half-life ~7 days): 5×7d = 35 days; 7×7d = 49 days for receptor baseline • CJC-1295 DAC (half-life ~8 days): 5×8d = 40 days minimum • Tesamorelin (half-life 26–30 min): 5×0.5h = 2.5 hours — essentially no carryover

Pharmacokinetic clearance (plasma concentration) is not the same as biological endpoint normalization. For downstream marker studies: • IGF-1 returns to baseline within 4–6 weeks after stopping GHRH analog protocols, regardless of compound half-life • Body composition changes from GLP-1 agonists persist for months post-washout (weight regain trajectory studies are themselves valid research designs) • Collagen remodeling initiated by BPC-157 or TB-500 may continue for weeks post-compound clearance due to fibroblast/TGF-β signaling cascade self-perpetuation • Telomere length changes from Epitalon are a permanent endpoint — "washout" is not a relevant concept Design your washout requirements based on the specific biomarker you intend to measure, not just plasma PK clearance.

For compounds with known receptor downregulation profiles (GHRPs: GHRP-2, GHRP-6, hexarelin show 50–80% GH response attenuation after 4–8 continuous weeks), cycle/off periods are incorporated to restore receptor sensitivity. Standard cycle structure for GHRP-containing protocols: • On-cycle: 8–12 weeks • Off/reduced interval: 4–6 weeks (or switch to GHRH-only during off weeks) • Or: 5-days-on / 2-days-off weekly micro-cycling Ipamorelin shows substantially less tachyphylaxis than hexarelin, GHRP-2, or GHRP-6, making it better suited for continuous protocols.

Every research record should capture, at minimum: • Date and time of administration • Compound name and lot/batch number (reference your COA) • Dose (mcg or mg) • Volume administered (mL) • Concentration of reconstituted solution (mcg/mL) • Route of administration (SC, IP, IV, intranasal, oral) • Injection site (for injectable routes) • Subject/animal ID • Observations: any behavioral or physiological notes within 2 hours post-administration • Vial storage condition (was it returned to fridge within 30 min?)

Label every reconstituted vial immediately upon mixing. Minimum label content: • Compound name • Reconstituted concentration (e.g., "5 mg/mL" or "500 mcg/0.1 mL") • Date of reconstitution • Expiry date (reconstituted vial expiry, not lyophilized expiry) • Solvent used (BAC water / sterile water / acetic acid) • Batch number from COA Use waterproof labeling or wrap paper labels with clear tape. Pen on the rubber stopper alone is not sufficient for multi-week vials — condensation from refrigerator cycling will fade ink.

For any protocol intended to produce measurable biomarker changes, capture a baseline before first administration and schedule interim measurements: • IGF-1: Baseline → Week 4 → Week 8 → Week 12 (or end-of-cycle) • Body composition (DEXA or BIA): Baseline → Week 6 → Week 12 (or end-of-cycle) • Fasting glucose / insulin: Baseline → monthly (especially for MK-677, GLP-1 agonist, and MOTS-c protocols) • Complete metabolic panel (CMP): Baseline → end-of-cycle for any 12-week+ protocol • Lipid panel: Baseline → end-of-cycle for GLP-1, GH-axis, or MOTS-c protocols Biomarker tracking converts a simple administration log into research-quality data. Without comparative endpoints, protocol execution is not research — it is administration.

Maintain records in both formats when possible. A spreadsheet (Google Sheets, Excel, or Airtable) enables filtering by date, compound, and batch — critical for identifying patterns across multiple protocols or detecting lot-to-lot variability across different Nexphoria shipments. For institutional research, maintain records per your IRB/IACUC protocol data retention requirements (typically 3–7 years). For independent lab use, a simple timestamped spreadsheet exported to PDF monthly is sufficient documentation discipline.

Synergistic stacks produce a combined effect larger than the sum of parts — most commonly seen in GH axis combinations. GHRH + GHRP co-administration produces 8–12× the GH response of either compound alone (Bowers 1998), due to complementary mechanisms: GHRH drives cAMP/PKA transcription of GH, while GHRPs inhibit somatostatin and amplify GH pulse amplitude. Additive stacks produce roughly the sum of individual effects — relevant for repair compounds (BPC-157 + TB-500 acting on complementary tissue repair pathways) and antioxidant/longevity compounds (NAD+ + GHK-Cu + Epitalon targeting different aging mechanisms without receptor overlap). Identify whether your stack rationale is synergistic or additive before designing administration timing, since synergistic stacks often require co-timing within a narrow window (e.g., GHRP + GHRH within 5–10 minutes for maximum GH amplitude), while additive stacks do not.

When multiple compounds share a receptor class, receptor competition or saturation can reduce individual compound efficacy. Key examples: • Multiple GLP-1R agonists: Do not co-administer semaglutide and tirzepatide — receptor saturation provides no additional GLP-1R occupancy, while increasing peptide load and potential tolerability issues • GH axis: Do not co-administer two GHRH analogs (e.g., CJC-1295 No DAC + tesamorelin). GHRH receptors saturate; no benefit, additive tachyphylaxis risk • MC1R compounds: GHK-Cu and Melanotan II both interact with melanocortin receptor pathways; simultaneous protocols produce confounded endpoint attribution When compounds share a receptor, compare their binding affinities (Ki values) and design sequential rather than simultaneous protocols if disambiguation is needed.

Administering 4+ compounds by subcutaneous injection in a single day creates site rotation pressure, increases cumulative injection trauma risk, and can complicate adverse effect attribution. Best practices: • Cap same-day SC injections at 3 compounds where possible • Consider route diversification (intranasal for Semax/Selank, oral for MK-677, topical for GHK-Cu serum applications) to reduce SC injection load • Use combination timing where half-life allows: GH axis protocols allow CJC-1295 DAC to be administered weekly while ipamorelin is administered daily — reducing daily injection count without sacrificing protocol design • Stagger long-half-life compounds to different days of the week